Chronic hepatitis D coinfection affects an estimated 12 million people globally, with higher prevalence in low-income and middle-income countries, especially the African and Western Pacific regions.

Gyre Therapeutics, Inc. (Gyre or Gyre Therapeutics) (Nasdaq: GYRE), a San Diego-based innovative commercial stage biopharmaceutical company with operations in the United States and China, today ...

When most people think about liver disease, they think about alcohol or hepatitis. What many don’t realize is that the most ...

The World Health Organization (WHO) released landmark Consolidated guidance and implementation handbook on hepatitis B and C, ...

Hepatitis B is one of the most widespread viral infections in the world, with hundreds of millions of people living with it today. Caused by the hepatitis B virus (HBV), this condition primarily ...

The publication aims to help countries translate WHO’s global guidance into practical actions to accelerate progress toward ...

The World Health Organization (WHO) released landmark Consolidated guidance and implementation handbook on hepatitis B and C , to support countries ...

The number of newborns vaccinated at birth against hepatitis B has fallen slightly over the past four years, according to the ...

Atea Pharmaceuticals (NASDAQ:AVIR) outlined progress in its hepatitis C (HCV) late-stage development program and provided an update on its newly expanded hepatitis E virus (HEV) pipeline during its ...

Good afternoon, everyone, and welcome to the Atea Pharmaceuticals' Fourth Quarter 2025 Financial Results and Business Update Conference Call. [Operator Instructions] I would now like to turn the call ...

Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected ...

Alcohol consumption leads to hormonal and inflammatory responses which affect both metabolic and cardiac systems ...